Membrane-associated CD40L and sCD40L in atherothrombotic disease

Summary

Recent data suggests that CD40L is involved in the pathogenesis of atherothrombotic disease. This review will focus on the history of CD40L, its role in platelet-mediated pathogenesis of atherothrombotic disease, its association to clinical syndromes and procedures, and its role in determining plaque rupture.

Keywords

CD40L - atherothrombotic disease - platelets - extracellular matrix - matrix metalloproteinase

• References

• 1 Hollenbaugh D, Grosmaire LS, Kullas CD. et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. Embo J 1992; 11 (12) 4313-21.
• 2 Clark EA. CD40: a cytokine receptor in search of a ligand. Tissue Antigens 1990; 36 (01) 33-6.
• 3 Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58 (01) 4-43.
• 4 Henn V, Steinbach S, Buchner K. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98 (04) 1047-54.
• 5 Inwald DP, McDowall A, Peters MJ. et al. CD40 Is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-8.
• 6 Armitage RJ, Fanslow WC, Strockbine L. et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357 6373 80-2.
• 7 Graf D, Korthauer U, Mages HW. et al. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 1992; 22 (12) 3191-4.
• 8 Lederman S, Yellin MJ, Krichevsky A. et al. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992; 175 (04) 1091-101.
• 9 Gauchat JF, Henchoz S, Mazzei G. et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365 6444 340-3.
• 10 Carbone E, Ruggiero G, Terrazzano G. et al. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med 1997; 185 (12) 2053-60.
• 11 Mach F, Schonbeck U, Sukhova GK. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 1997; 94 (05) 1931-6.
• 12 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391 6667 591-4.
• 13 Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996; 61: 1-77.
• 14 Chan FK, Chun HJ, Zheng L. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288 5475 2351-4.
• 15 Morris AE, Remmele Jr. RL, Klinke R. et al. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999; 274 (01) 418-23.
• 16 Kroczek RA, Graf D, Brugnoni D. et al. Defective expression of CD40 ligand on T cells causes “X-linked immunodeficiency with hyper-IgM (HIGM1)”. Immunol Rev 1994; 138: 39-59.
• 17 Foy TM, Aruffo A, Bajorath J. et al. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14: 591-617.
• 18 Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340 (02) 115-26.
• 19 Mach F, Schonbeck U, Sukhova GK. et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394 6689 200-3.
• 20 Schonbeck U, Sukhova GK, Shimizu K. et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000; 97 (13) 7458-63.
• 21 Lutgens E, Gorelik L, Daemen MJ. et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5 (11) 1313-6.
• 22 Andre P, Prasad KS, Denis CV. et al. CD40L stabilizes arterial thrombi by a beta3 integrin—dependent mechanism. Nat Med 2002; 8 (03) 247-52.
• 23 Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20 (10) 2322-8.
• 24 Slupsky JR, Kalbas M, Willuweit A. et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80 (06) 1008-14.
• 25 Bavendiek U, Libby P, Kilbride M. et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002; 277 (28) 25032-9.
• 26 Schonbeck U, Mach F, Sukhova GK. et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156 (01) 7-14.
• 27 Aukrust P, Muller F, Ueland T. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100 (06) 614-20.
• 28 Viallard JF, Solanilla A, Gauthier B. et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99 (07) 2612-4.
• 29 Heeschen C, Dimmeler S, Hamm CW. et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348 (12) 1104-11.
• 30 Wykes M, Poudrier J, Lindstedt R. et al. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol 1998; 28 (02) 548-59.
• 31 Hollenbaugh D, Mischel-Petty N, Edwards CP. et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995; 182 (01) 33-40.
• 32 Kiener PA, Moran-Davis P, Rankin BM. et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995; 155 (10) 4917-25.
• 33 Wiley JA, Geha R, Harmsen AG. Exogenous CD40 ligand induces a pulmonary inflammation response. J Immunol 1997; 158 (06) 2932-8.
• 34 Melter M, Reinders ME, Sho M. et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angio-genesis in vivo. Blood 2000; 96 (12) 3801-8.
• 35 Urbich C, Dernbach E, Aicher A. et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106 (08) 981-6.
• 36 Mazzei GJ, Edgerton MD, Losberger C. et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995; 270 (13) 7025-8.
• 37 Bajorath J, Aruffo A. Construction and analysis of a detailed three-dimensional model of the ligand binding domain of the human B cell receptor CD40. Proteins 1997; 27 (01) 59-70.
• 38 van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67 (01) 2-17.
• 39 Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107 (08) 1123-8.
• 40 May AE, Kalsch T, Massberg S. et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106 (16) 2111-7.
• 41 Garlichs CD, Eskafi S, Raaz D. et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86 (06) 649-55.
• 42 Garlichs CD, John S, Schmeisser A. et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104 (20) 2395-400.
• 43 Semb AG, van Wissen S, Ueland T. et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003; 41 (02) 275-9.
• 44 Marx N, Imhof A, Froehlich J. et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7.
• 45 Peng DQ, Zhao SP, Li YF. et al. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002; 319 (01) 19-26.
• 46 Cipollone F, Mezzetti A, Porreca E. et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106 (04) 399-402.
• 47 Nannizzi-Alaimo L, Rubenstein MH, Alves VL. et al. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002; 105 (24) 2849-54.
• 48 Krotz F, Schiele TM, Zahler S. et al. Sustained platelet activation following intra-coronary beta irradiation. Am J Cardiol 2002; 90 (12) 1381-4.
• 49 Blake GJ, Ostfeld RJ, Yucel EK. et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003; 23 (01) e11-4.
• 50 Schonbeck U, Varo N, Libby P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104 (19) 2266-8.
• 51 Aikawa M, Voglic SJ, Sugiyama S. et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999; 100 (11) 1215-22.
• 52 Schonbeck U, Gerdes N, Varo N. et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106 (23) 2888-93.
• 53 Wagner AH, Gebauer M, Guldenzoph B. et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22 (11) 1784-9.
• 54 Li D, Liu L, Chen H. et al. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 816-21.
• 55 Schonbeck U, Mach F, Sukhova GK. et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ Res 1997; 81 (03) 448-54.
• 56 Mach F, Schonbeck U, Fabunmi RP. et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154 (01) 229-38.
• 57 Mach F, Schonbeck U, Bonnefoy JY. et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96 (02) 396-9.
• 58 Morton LF, Barnes MJ. Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V. Atherosclerosis 1982; 42 (01) 41-51.
• 59 Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990; 11 Suppl E 3-19.
• 60 Horton DB, Libby P, Schonbeck U. Ligation of CD40 on vascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity. Ann N Y Acad Sci 2001; 947: 329-36.
• 61 Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91 (11) 2844-50.
• 62 Libby P, Lee RT. Matrix matters. Circulation 2000; 102 (16) 1874-6.
• 63 Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12 (05) 621-8.